Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

79.40 UNCHANGED

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

3 Healthcare Stocks That Concern Us

April 28, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID...

Via StockStory

Topics Stocks

Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today ↗

April 25, 2025

Via Benzinga

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

April 23, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

April 21, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know

April 16, 2025

A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that...

Via StockStory

Topics Artificial Intelligence Economy Government

$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today ↗

April 16, 2025

Via Benzinga

Investors seeking growth at a reasonable cost should explore CORCEPT THERAPEUTICS INC (NASDAQ:CORT). ↗

April 15, 2025

NASDAQ:CORT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Via Chartmill

3 Biopharmaceutical Stocks Bucking the Sell-Off

April 10, 2025

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

Via MarketBeat

Topics World Trade

Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks

April 10, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

April 08, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

April 07, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4) ↗

April 06, 2025

Mid-cap stocks surged in the past week, including CORT, COOP, and CRWV. GOOG may rent AI servers from CRWV. PRGS and LOAR reported strong results.

Via Benzinga

Topics Artificial Intelligence Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 01, 2025

Via Benzinga

Top stock movements in today's session. ↗

March 31, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings) ↗

March 31, 2025

Via Benzinga

Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast ↗

March 31, 2025

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.

Via Benzinga

Why Is Corcept (CORT) Stock Soaring Today

March 31, 2025

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving...

Via StockStory

Topics Artificial Intelligence

Monday's session: top gainers and losers ↗

March 31, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 31, 2025

Via Benzinga

These stocks are gapping in today's session ↗

March 31, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet ↗

March 31, 2025

Via Benzinga

Topics Stocks

Mr. Cooper Group, Southern States Bancshares, Corcept Therapeutics And Other Big Stocks Moving Higher On Monday ↗

March 31, 2025

Via Benzinga

Monday's pre-market session: top gainers and losers ↗

March 31, 2025

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Via Chartmill

Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March ↗

March 31, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 31, 2025

Via Benzinga

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

March 31, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

3 Reasons to Sell CORT and 1 Stock to Buy Instead

March 26, 2025

Corcept currently trades at $58.76 and has been a dream stock for shareholders. It’s returned 434% since March 2020, blowing past the S&P 500’s 117% gain. The company has also beaten the index over the...

Via StockStory

Topics Stocks

CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued. ↗

March 24, 2025

Uncover the potential of CORCEPT THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive...

Via Chartmill

3 Growth Stocks in Hot Water

March 19, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Via StockStory

1 Small-Cap Stock on Our Buy List and 2 to Avoid

March 14, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.